Afm13 clinical trial
WebAFM13 in clinical trials A completed Phase 1 study ( NCT01221571) assessed the safety, tolerability, and activity of AFM13 in 28 patients with HL that returned despite treatment … WebTo assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two …
Afm13 clinical trial
Did you know?
WebApr 14, 2024 · American Association for Cancer Research (AACR) 2024 Preview – Top Data Readouts. The upcoming AACR 2024 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we … WebNov 15, 2024 · As a single agent, AFM13 has limited clinical activity against HL, likely due to the reduced effector function of autologous NK cells in these patients, which provides the rationale for the combination of AFM13 with allogeneic NK cells. ... CONCLUSIONS: This is the first clinical trial to date using an ICE® construct precomplexed with cytokine ...
WebApr 10, 2024 · AFM13, a bispecific tetravalent ICE® molecule, is designed for high affinity binding, both to CD16A on NK cells and macrophages, and to CD30 on lymphoma cells. … WebJul 1, 2024 · Immune cell engagers have been developed to overcome barriers related to deficient cancer recognition and NK-cell activation. AFM13 is a tetravalent bispecific …
WebDec 22, 2014 · GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (GHSG-AFM13) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. WebResearchers at Columbia University are carrying out an open-label Phase 1/2 clinical trial ( NCT03192202) assessing AFM13 as a therapy for CTCL in an estimated 18 patients. Other information AFM13 was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in September 2009. ***
WebApr 10, 2024 · The antibody, innate cell engager AFM13, acts as a bridge between the two cell types, helping the natural killer cells more effectively fight the cancer. Prior studies with AFM13 showed preliminary efficacy in clinical trials of patients with Hodgkin lymphoma, T-cell lymphoma, and peripheral T-cell lymphoma.
WebAug 30, 2024 · Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin … championship wrestling from hollywood wikiWebAug 1, 2015 · Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK … championship wrestling from hollywood newsWebSearch clinical trials for: AFM13 . Total 5 results. NCT04074746. Recruiting. Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas. championship wrestling presented by carshieldWebDec 10, 2024 · AFM13 is a first-in-class innate cell engager (ICE ®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. hap therapistWebJul 1, 2024 · AFM13-NK complex cells exhibited enhanced responses to CD30+lymphomas in vitroand in vivo. Conclusions: We identify AFM13 as a promising combination with … hapthatra the radiantWebDec 7, 2024 · This updated analysis of the AFM13 monotherapy study in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation showed an Objective Response Rate (ORR) of 42 percent (6/14) and demonstrated clinical activity after brentuximab vedotin failure in two of four patients. championship wrestling from memphis logoWebNov 19, 2024 · Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650 . © 2024 by The American Society … hap therapie